KIR2DL3 and graft versus host disease: As a result, given that Russo et al. found that many recipients with KIR/HLA incompatibility had GvHD at day 30, it may be inferred that the PTCy therapy specifically eliminates responsive alloreactive KIR2DL NK cells [44].